Crescent Biopharma (CBIO) Capital Expenditures (2013 - 2026)

Crescent Biopharma (CBIO) has 14 years of Capital Expenditures data on file, last reported at $147000.0 in Q1 2026.

• Capital Expenditures for Q1 2026 came in at $147000.0, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was $158000.0 (up 6137.66% YoY), and the FY2025 annual result was $11000.0, up 10.31% from the prior year.
• Capital Expenditures grew to $147000.0 in Q1 2026 per CBIO's latest filing, from -$715000.0 in the prior quarter.
• Over five years, Capital Expenditures peaked at $586000.0 in Q3 2025 and troughed at -$715000.0 in Q4 2025.
• A 5-year average of $19539.8 and a median of $7652.5 in 2023 frame the typical range for Capital Expenditures.
• The sharpest annual moves came in 2022 and 2023: Capital Expenditures slumped 99.96% in 2022, then soared 80000.0% in 2023.
• A 5-year view of Capital Expenditures shows it stood at $1.0 in 2022, then soared by 80000.0% to $801.0 in 2023, then jumped by 216.23% to $2533.0 in 2024, then slumped by 28327.4% to -$715000.0 in 2025, then jumped by 120.56% to $147000.0 in 2026.
• Business Quant data shows CBIO's Capital Expenditures at $147000.0 in Q1 2026, -$715000.0 in Q4 2025, and $586000.0 in Q3 2025.